VRTX ファイナンス： Vertex Pharmaceuticals Inc AI分析



財務状況

VRTX 財務

Vertex Pharmaceuticals Inc

$435.17

1.24%

$5.35

終値： May 11, 16:00:00 GMT-4

$437.19

0.46%

$2.01

プレマーケット： May 12, 06:42:16 GMT-4

概要予測収入配当財務状況

主要データ

前終値

$429.82

始値

$432.3

当日レンジ

$428.5 - $442.15

52週レンジ

$362.5 - $507.92

取引高

1.2M

平均取引高

1.3M

配当利回り

1株当たり利益(TTM)

16.87

時価総額

$111.2B

VRTXとは何ですか？

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

特徴

Markets

News

利用規約プライバシーポリシー

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
収入	12,218	2,986	3,190	3,076	2,964	2,770
収益成長率（YoY）	10%	8%	10%	11%	12%	3%
収益のコスト	1,681	392	466	414	407	363
売上総利益	10,536	2,594	2,724	2,661	2,557	2,407
販売、一般および管理	1,850	493	487	445	424	396
研究開発	3,891	961	973	977	978	979
運営費用	5,741	1,455	1,461	1,420	1,403	1,378
その他の非営業収入（費用）	-2	0	0	-8	6	-2
税引前利益	5,165	1,252	1,331	1,298	1,283	730
所得税費	827	221	139	215	250	84
純利益	4,338	1,031	1,191	1,082	1,032	646
純利益成長率	-539%	60%	30%	4%	-129%	-41%
流通済み株式数（希薄化後）	256.3	256.3	256.2	257.6	258.9	259.5
株式変動（前年比）	-1%	-1%	0%	-1%	0%	-1%
EPS（希薄化）	16.92	4.02	4.65	4.2	3.99	2.49
EPS成長率	-544%	61%	31%	5%	-129%	-41%
フリーキャッシュフロー	3,710	1,294	348	1,139	927	778
1株当たりフリーキャッシュフロー	--	--	--	--	--	--
粗利益	86.23%	86.87%	85.39%	86.5%	86.26%	86.89%
営業利益率	39.24%	38.11%	39.56%	40.31%	38.9%	37.11%
利益率	35.5%	34.52%	37.33%	35.17%	34.81%	23.32%
フリーキャッシュフロー利益率	30.36%	43.33%	10.9%	37.02%	31.27%	28.08%
EBITDA	5,012	1,193	1,317	1,294	1,204	1,076
EBITDAマージン	41.02%	39.95%	41.28%	42.06%	40.62%	38.84%
D&A による EBITDA	217	55	55	54	51	48
営業利益	4,795	1,138	1,262	1,240	1,153	1,028
営業利益率	39.24%	38.11%	39.56%	40.31%	38.9%	37.11%
実効税率	16.01%	17.65%	10.44%	16.56%	19.48%	11.5%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

収入

12,218

2,986

3,190

3,076

2,964

2,770

収益成長率（YoY）

10%

11%

12%

収益のコスト

1,681

392

466

414

407

363

売上総利益

10,536

2,594

2,724

2,661

2,557

2,407

販売、一般および管理

1,850

493

487

445

424

396

研究開発

3,891

961

973

977

978

979

運営費用

5,741

1,455

1,461

1,420

1,403

1,378

その他の非営業収入（費用）

-2

-8

-2

税引前利益

5,165

1,252

1,331

1,298

1,283

730

所得税費

827

221

139

215

250

純利益

4,338

1,031

1,191

1,082

1,032

646

純利益成長率

-539%

60%

30%

-129%

-41%

流通済み株式数（希薄化後）

256.3

256.2

257.6

258.9

259.5

株式変動（前年比）

-1%

EPS（希薄化）

16.92

4.02

4.65

4.2

3.99

2.49

EPS成長率

-544%

61%

31%

-129%

-41%

フリーキャッシュフロー

3,710

1,294

348

1,139

927

778

1株当たりフリーキャッシュフロー

粗利益

86.23%

86.87%

85.39%

86.5%

86.26%

86.89%

営業利益率

39.24%

38.11%

39.56%

40.31%

38.9%

37.11%

利益率

35.5%

34.52%

37.33%

35.17%

34.81%

23.32%

フリーキャッシュフロー利益率

30.36%

43.33%

10.9%

37.02%

31.27%

28.08%

EBITDA

5,012

1,193

1,317

1,294

1,204

1,076

EBITDAマージン

41.02%

39.95%

41.28%

42.06%

40.62%

38.84%

D&A による EBITDA

217

営業利益

4,795

1,138

1,262

1,240

1,153

1,028

営業利益率

39.24%

38.11%

39.56%

40.31%

38.9%

37.11%

実効税率

16.01%

17.65%

10.44%

16.56%

19.48%

11.5%

Follow-Up Questions

Vertex Pharmaceuticals Inc'in temel mali tabloları nelerdir?



Son mali tabloya (Form-10K) göre, Vertex Pharmaceuticals Inc'in toplam varlıkları $0 olup, net 損失 $0'dir.

VRTX'ün temel finansal oranları nelerdir?



Vertex Pharmaceuticals Inc'in cari oranı 0, net kâr marjı 0, hisse başına satış $0'dir.

Vertex Pharmaceuticals Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?



Vertex Pharmaceuticals Inc の最大収益セグメントは Other で、最新の利益発表における収益は 644,700,000 です。地域別に見ると、Other Collaborative and Royalty が Vertex Pharmaceuticals Inc の主要市場であり、収益は 30,700,000 です。

Vertex Pharmaceuticals Inc kârlı mı?



いいえ, son mali tablolara göre Vertex Pharmaceuticals Inc'in net 損失 $0'dir.

Vertex Pharmaceuticals Inc'in herhangi bir yükümlülüğü var mı?



いいえ, Vertex Pharmaceuticals Inc'in yükümlülüğü 0'dir.

Vertex Pharmaceuticals Inc'in tedavüldeki hisse sayısı kaçtır?



Vertex Pharmaceuticals Inc'in toplam tedavüldeki hisse sayısı 0'dir.

Vertex Pharmaceuticals Inc (VRTX) 財務

VRTX 株価推移チャート

主要データ

前終値

始値

当日レンジ

52週レンジ

取引高

平均取引高

配当利回り

1株当たり利益(TTM)

時価総額

VRTXとは何ですか？

Vertex Pharmaceuticals Inc (VRTX) 財務

VRTX 株価推移チャート

主要データ

前終値

始値

当日レンジ

52週レンジ

取引高

平均取引高

配当利回り

1株当たり利益(TTM)

時価総額

VRTXとは何ですか？

VRTX 収入

Follow-Up Questions

Vertex Pharmaceuticals Inc'in temel mali tabloları nelerdir?

VRTX'ün temel finansal oranları nelerdir?

Vertex Pharmaceuticals Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Vertex Pharmaceuticals Inc kârlı mı?

Vertex Pharmaceuticals Inc'in herhangi bir yükümlülüğü var mı?

Vertex Pharmaceuticals Inc'in tedavüldeki hisse sayısı kaçtır?